The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation

Achim A. Jungbluth; Scott Ely; Maurizio DiLiberto; Ruben Niesvizky; Barbara Williamson; Denise Frosina; Yao Tseng Chen; Nina Bhardwaj; Selina Chen-Kiang; Lloyd J. Old; Hearn Jay Cho

doi:10.1182/blood-2004-12-4931

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation

Achim A. Jungbluth, Scott Ely, Maurizio DiLiberto, Ruben Niesvizky, Barbara Williamson, Denise Frosina, Yao Tseng Chen, Nina Bhardwaj, Selina Chen-Kiang, Lloyd J. Old, Hearn Jay Cho

Research output: Contribution to journal › Review article › peer-review

176 Scopus citations

Abstract

Multiple myeloma is a malignancy of plasma cells. Vaccine immunotherapy is among the novel therapeutic strategies under investigation for this disease. To identify myeloma-associated antigens as potential targets for vaccine immunotherapy, we surveyed a comprehensive panel of bone marrow specimens from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma for expression of cancer-testis (CT) antigens. Immunohistochemistry (IHC) demonstrated that 82% of stage-III myeloma specimens expressed the CT antigen CT7 (also known as melanoma antigen C1 [MAGE-C1]) and 70% expressed MAGE-A3/6. Messenger RNA for CT7 and MAGE-A family members was detected in 87% and 100% of stage-III samples, respectively. CT7 protein expression increased with advanced stage of disease. Higher levels of CT7 and MAGE-A3/6 proteins also correlated with elevated plasma-cell proliferation. These results show that CT7 and MAGE-A3/6 are promising myeloma-associated antigens for application in vaccine immunotherapy. Furthermore, the common expression and correlation with proliferation suggest a possible pathogenic role for these proteins in myeloma.

Original language	English
Pages (from-to)	167-174
Number of pages	8
Journal	Blood
Volume	106
Issue number	1
DOIs	https://doi.org/10.1182/blood-2004-12-4931
State	Published - 1 Jul 2005

Access to Document

10.1182/blood-2004-12-4931

Cite this

Jungbluth, A. A., Ely, S., DiLiberto, M., Niesvizky, R., Williamson, B., Frosina, D., Chen, Y. T., Bhardwaj, N., Chen-Kiang, S., Old, L. J., & Cho, H. J. (2005). The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood, 106(1), 167-174. https://doi.org/10.1182/blood-2004-12-4931

@article{b1509a7f9d8848fbb5f9c2e1946b593b,

title = "The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation",

abstract = "Multiple myeloma is a malignancy of plasma cells. Vaccine immunotherapy is among the novel therapeutic strategies under investigation for this disease. To identify myeloma-associated antigens as potential targets for vaccine immunotherapy, we surveyed a comprehensive panel of bone marrow specimens from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma for expression of cancer-testis (CT) antigens. Immunohistochemistry (IHC) demonstrated that 82% of stage-III myeloma specimens expressed the CT antigen CT7 (also known as melanoma antigen C1 [MAGE-C1]) and 70% expressed MAGE-A3/6. Messenger RNA for CT7 and MAGE-A family members was detected in 87% and 100% of stage-III samples, respectively. CT7 protein expression increased with advanced stage of disease. Higher levels of CT7 and MAGE-A3/6 proteins also correlated with elevated plasma-cell proliferation. These results show that CT7 and MAGE-A3/6 are promising myeloma-associated antigens for application in vaccine immunotherapy. Furthermore, the common expression and correlation with proliferation suggest a possible pathogenic role for these proteins in myeloma.",

author = "Jungbluth, {Achim A.} and Scott Ely and Maurizio DiLiberto and Ruben Niesvizky and Barbara Williamson and Denise Frosina and Chen, {Yao Tseng} and Nina Bhardwaj and Selina Chen-Kiang and Old, {Lloyd J.} and Cho, {Hearn Jay}",

year = "2005",

month = jul,

day = "1",

doi = "10.1182/blood-2004-12-4931",

language = "English",

volume = "106",

pages = "167--174",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation

AU - Jungbluth, Achim A.

AU - Ely, Scott

AU - DiLiberto, Maurizio

AU - Niesvizky, Ruben

AU - Williamson, Barbara

AU - Frosina, Denise

AU - Chen, Yao Tseng

AU - Bhardwaj, Nina

AU - Chen-Kiang, Selina

AU - Old, Lloyd J.

AU - Cho, Hearn Jay

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Multiple myeloma is a malignancy of plasma cells. Vaccine immunotherapy is among the novel therapeutic strategies under investigation for this disease. To identify myeloma-associated antigens as potential targets for vaccine immunotherapy, we surveyed a comprehensive panel of bone marrow specimens from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma for expression of cancer-testis (CT) antigens. Immunohistochemistry (IHC) demonstrated that 82% of stage-III myeloma specimens expressed the CT antigen CT7 (also known as melanoma antigen C1 [MAGE-C1]) and 70% expressed MAGE-A3/6. Messenger RNA for CT7 and MAGE-A family members was detected in 87% and 100% of stage-III samples, respectively. CT7 protein expression increased with advanced stage of disease. Higher levels of CT7 and MAGE-A3/6 proteins also correlated with elevated plasma-cell proliferation. These results show that CT7 and MAGE-A3/6 are promising myeloma-associated antigens for application in vaccine immunotherapy. Furthermore, the common expression and correlation with proliferation suggest a possible pathogenic role for these proteins in myeloma.

AB - Multiple myeloma is a malignancy of plasma cells. Vaccine immunotherapy is among the novel therapeutic strategies under investigation for this disease. To identify myeloma-associated antigens as potential targets for vaccine immunotherapy, we surveyed a comprehensive panel of bone marrow specimens from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma for expression of cancer-testis (CT) antigens. Immunohistochemistry (IHC) demonstrated that 82% of stage-III myeloma specimens expressed the CT antigen CT7 (also known as melanoma antigen C1 [MAGE-C1]) and 70% expressed MAGE-A3/6. Messenger RNA for CT7 and MAGE-A family members was detected in 87% and 100% of stage-III samples, respectively. CT7 protein expression increased with advanced stage of disease. Higher levels of CT7 and MAGE-A3/6 proteins also correlated with elevated plasma-cell proliferation. These results show that CT7 and MAGE-A3/6 are promising myeloma-associated antigens for application in vaccine immunotherapy. Furthermore, the common expression and correlation with proliferation suggest a possible pathogenic role for these proteins in myeloma.

UR - http://www.scopus.com/inward/record.url?scp=22044451852&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-12-4931

DO - 10.1182/blood-2004-12-4931

M3 - Review article

C2 - 15761016

AN - SCOPUS:22044451852

SN - 0006-4971

VL - 106

SP - 167

EP - 174

JO - Blood

JF - Blood

IS - 1

ER -

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation

Abstract

Access to Document

Fingerprint

Cite this